ArticleESMO open2025
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.
H S Rugo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
44 papers cite it
this paperpooled ittrialcites it